Tactic Pharma LLC Amends Monopar Therapeutics Stake
Ticker: MNPR · Form: SC 13D/A · Filed: Dec 17, 2024 · CIK: 1645469
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
Related Tickers: CPRX
TL;DR
Tactic Pharma just updated their Monopar Therapeutics holdings. Big move incoming?
AI Summary
Tactic Pharma LLC, through an amendment filed on December 17, 2024, has updated its Schedule 13D regarding Monopar Therapeutics Inc. The filing indicates a change in beneficial ownership, with Tactic Pharma LLC now holding a significant stake in the company. The specific percentage and number of shares are detailed within the full filing.
Why It Matters
This amendment signals a potential shift in control or influence over Monopar Therapeutics, which could impact its strategic direction and stock performance.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate actions, introducing uncertainty and potential volatility.
Key Players & Entities
- Tactic Pharma LLC (company) — Filing entity
- Monopar Therapeutics Inc (company) — Subject company
- Andrew Mazar (person) — Group member
- Chandler Robinson (person) — Group member
- Michael Brown (person) — Group member
- Thomas O'Halloran (person) — Group member
FAQ
What is the exact percentage of Monopar Therapeutics' common stock that Tactic Pharma LLC beneficially owns after this amendment?
The filing does not explicitly state the exact percentage of beneficial ownership in the provided text, but it is an amendment to a Schedule 13D, indicating a change in ownership that crosses a reporting threshold.
When was the previous Schedule 13D filing by Tactic Pharma LLC or its group members?
The provided text is an amendment (Amendment No. 1) filed on December 17, 2024, indicating a prior filing existed but its date is not specified here.
What is the business address of Tactic Pharma LLC?
The business address for Tactic Pharma LLC is 598 Rockefeller Rd., Lake Forest, IL, 60045.
Who are the individuals listed as group members in this filing?
The individuals listed as group members are Andrew Mazar, Chandler Robinson, Michael Brown, and Thomas O'Halloran.
What is the CUSIP number for Monopar Therapeutics Inc. common stock?
The CUSIP number for Monopar Therapeutics Inc. common stock is 61023L207.
Filing Stats: 1,290 words · 5 min read · ~4 pages · Grade level 15.2 · Accepted 2024-12-17 17:01:42
Key Financial Figures
- $0.001 — S INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securitie
Filing Documents
- tpllc20241217_sc13da.htm (SC 13D/A) — 92KB
- 0001437749-24-037745.txt ( ) — 94KB
is amended and restated to read as follows
Item 5 is amended and restated to read as follows: (a,b) Refer to the cover pages. All percentages are calculated based on 5,277,796 shares of Common Stock outstanding as of December 16, 2024. (c) Except as described in Item 6, the the Reporting Persons have not effected any transaction in the securities of the Issuer during the past 60 days. (d) Not applicable. (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.
is hereby supplemented as follows
Item 6 is hereby supplemented as follows: On December 9, 2024, TacticGem LLC ("TacticGem") made a pro rata distribution of all of the shares of Common Stock that were held by it to its members, Tactic Pharma and Gem Pharmecuticals, LLC ("Gem"). Tactic Pharma and the other Reporting Persons were already deemed to beneficially own their pro rata interest in the shares held indirectly by TacticGem, so the distribution did not result in any change to the beneficial ownership of the Reporting Persons. The Reporting Persons and Gem agreed to lock-up provisions with each other prohibiting sales of the distributed Common Stock until December 31, 2025, without the mutual consent of representatives of both Tactic Pharma and Gem. In addition, the Reporting Persons will continue to have the same registration rights previously exercisable through TacticGem, but the lock-up agreement also provided that neither the Reporting Persons nor Gem would exercise such rights until December 31, 2025, without the mutual consent of representatives of both Tactic Pharma and Gem.
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. TACTIC PHARMA LLC Dated: December 16, 2024 By: /s/ Chandler Robinson Chandler Robinson Managing Member Dated: December 16, 2024 By: /s/ Chandler Robinson Chandler Robinson Dated: December 16, 2024 By: /s/ Michael Brown Michael Brown Dated: December 16, 2024 By: /s/ Thomas O'Halloran Thomas O'Halloran Dated: December 16, 2024 By: /s/ Andrew Mazar Andrew Mazar